Digital Biomarkers Propel Healthcare to New Heights
San Francisco, Monday, 21 July 2025.
Digital biomarkers like HRV and VO2max are reshaping personal health management, with the market projected to expand from $3.4 billion in 2023 to over $21 billion by 2032.
Transformative Potential of Digital Biomarkers
Digital biomarkers, particularly Heart Rate Variability (HRV) and VO2max, are becoming pivotal in personal health management. These biomarkers allow individuals to track their health metrics in real time, providing a thorough understanding of stress levels and recovery processes. The global digital biomarkers market is expected to grow significantly, from $3.4 billion in 2023 to over $21 billion by 2032, reflecting a compound annual growth rate (CAGR) of 22.8% [1].
Expanding Applications in Healthcare
As healthcare systems transition towards digital therapeutics, these biomarkers are proving invaluable. HRV, for example, provides insights into the autonomic nervous system’s balance, helping to tailor recovery strategies for athletes and patients alike. Furthermore, it plays a crucial role in detecting chronic stress and burnout, thereby enabling timely interventions [1]. VO2max, an established measure of cardiovascular fitness, continues to provide crucial data on endurance, biological aging, and mortality risk [1].
Integration with Wearable Technology
The integration of digital biomarkers with popular wearable technology, such as Garmin and Fitbit, marks a significant advancement in accessible healthcare. Thryve’s API, for instance, exemplifies how HRV data synchronization across devices can improve health app functionalities by offering personalized insights and real-time stress patterns [1]. These innovations are paving the way for preventive healthcare strategies by enabling in-depth health monitoring outside clinical settings.
Future Directions in Clinical Practice
Looking ahead, the potential for digital biomarkers to be integrated within clinical practice is immense. This would support a more proactive approach to healthcare, where data-driven insights into a patient’s health can lead to more effective prevention and treatment plans. Sanofi’s establishment of the DBM Innovation Lab exemplifies this shift, as they work on accelerating the adoption of digital biomarkers in clinical trials to improve patient outcomes [2].